| Autor: |
Spinola-Castro AM; Serviço de Endocrinologia Pediátrica, Departamento de Pediatria, Universidade Federal de São Paulo, SP, Brazil. aspinola.dped@epm.br, Siviero-Miachon AA, da Silva MT, Guerra-Junior G |
| Jazyk: |
portugalština |
| Zdroj: |
Arquivos brasileiros de endocrinologia e metabologia [Arq Bras Endocrinol Metabol] 2008 Jul; Vol. 52 (5), pp. 818-32. |
| DOI: |
10.1590/s0004-27302008000500014 |
| Abstrakt: |
Acquired Immunodeficiency Syndrome (Aids) was initially related to HIV-associated wasting syndrome, and its metabolic disturbances to altered body composition. After Highly Active Antiretroviral Therapy (HAART) was started, malnutrition has declined and HIV-associated lipodystrophy syndrome has emerged as an important metabolic disorder. Aids is also characterized by hormonal disturbances, principally in growth hormone/insulin-like growth factor 1 (GH/IGF-1) axis. The use of recombinant human GH (hrGH) was formerly indicated to treat wasting syndrome, in order to increase lean body mass. Even though the use of hrGH in lipodystrophy syndrome has been considered, the decrease in insulin sensitivity is a limitation for its use, which has not been officially approved yet. Diversity in therapeutic regimen is another limitation to its use in Aids patients. The present study has reviewed the main HIV-related endocrine-metabolic disorders as well as the use of hrGH in such conditions. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
